Rare surgically correctable form of primary aldosteronism

Rare surgically correctable form of primary aldosteronism refers to a subset of primary aldosteronism (also known as Conn syndrome when caused by an aldosterone-producing adenoma) in which excessive production of the hormone aldosterone by one or both adrenal glands can be definitively treated through surgical intervention. Primary aldosteronism is characterized by autonomous overproduction of aldosterone, leading to sodium retention, potassium loss, and suppression of the renin-angiotensin system. This results in resistant hypertension (high blood pressure), hypokalemia (low potassium levels), metabolic alkalosis, and increased cardiovascular risk including stroke, heart attack, and cardiac fibrosis. The surgically correctable forms most commonly include unilateral aldosterone-producing adenoma (APA) and, less frequently, unilateral adrenal hyperplasia. These conditions affect the endocrine and cardiovascular systems primarily, with secondary effects on the kidneys and electrolyte balance. Patients may experience muscle weakness, fatigue, headaches, excessive thirst, and frequent urination due to hypokalemia and hypertension. Some cases may be associated with somatic mutations in genes such as KCNJ5, ATP1A1, ATP2B3, or CACNA1D within the adenoma tissue. Diagnosis involves biochemical screening with the aldosterone-to-renin ratio, confirmatory testing, and adrenal vein sampling to lateralize the source of aldosterone excess. Surgical treatment, typically laparoscopic unilateral adrenalectomy, is the definitive therapy for unilateral disease and can result in cure or significant improvement of hypertension and normalization of potassium levels. Preoperative treatment with mineralocorticoid receptor antagonists such as spironolactone or eplerenone is used to control blood pressure and correct hypokalemia before surgery.

Common questions about Rare surgically correctable form of primary aldosteronism